scholarly journals Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Weijie Gu ◽  
Junlong Wu ◽  
Xiaohang Liu ◽  
Hailiang Zhang ◽  
Guohai Shi ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Biomarker ◽  
Target Therapy ◽  
Muscle Loss ◽  
Skeletal Muscle Loss

scholarly journals Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma

2019 ◽  
Vol 30 ◽  
pp. v391-v392
Author(s):  
C. Alves Costa Silva ◽  
D. Afonso ◽  
E. Colomba ◽  
G. Le Teuff ◽  
L. Derosa ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Renal Cell Carcinoma ◽  
Adverse Event ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Muscle Loss ◽  
Skeletal Muscle Loss

Skeletal muscle density as a positive predictive factor for nivolumab therapy in patients with metastatic renal cell carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17107-e17107
Author(s):  
Meltem Ekenel ◽  
Murat Sari ◽  
Samil Aliyev ◽  
Mert Basaran
Keyword(s):  
Skeletal Muscle ◽  
Renal Cell Carcinoma ◽  
Adipose Tissue ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Predictive Factor ◽  
Renal Cell ◽  
Intermediate Risk ◽  
Second Line ◽  
Muscle Density

e17107 Background: Immunotherapy has shown promising clinical responses in patients with metastatic Renal Cell Carcinoma (mRCC) at second-line therapy. Since objective response rates are highly variable, it is utmost important to identify patients who may benefit from immunotherapy to avoid unnecessary adverse effects and costs. Therefore, predictive as well as prognostic markers need to be studied extensively. To our knowledge, none of the body composition measurements such as fat content or skeletal muscle density have been assessed for this purpose. The objective of the current study is to analyze whether skeletal muscle (either muscle mass or muscle density) and adipose tissue play a prognostic role in patients with mRCC who were treated with immunotherapy at second line. Methods: We retrospectively analyzed 14 patients with mRCC who were progressed after tyrosine kinase inhibitor therapy and treated with Nivolumab between March 2016 and September 2019. Skeletal muscle density (SMD), skeletal muscle and adipose tissue were assessed with computed tomography imaging. Overall Survival (OS) and Progression Free Survival (PFS) were estimated by using the Kaplan-Meier method. Results: The median OS was 13,1 months and it was strongly associated with SMD; the median OS was significantly longer in patients with high SMD compared to patients with low SMD (6,9 months vs 18,5 months; P < 0,05). Also in our analysis, SMD separated the intermediate-risk group into 2 groups with different median OS periods, ranging from 8,1 months (95% confidence interval [95% CI], 5,1 months-11,1 months) in patients with intermediate-risk Heng score and low SMD to 21,5 months (95% CI, 14 months-27 months) in patients with an intermediate-risk Heng score and high SMD. Other parameters calculated for adipose tissue or skeletal muscle did not cause any significant change in survival analysis. Conclusions: High SMD appears to be associated with improved outcome in our small patient population. It could be a predictive factor when immunotherapy, Nivolumab, is considered for therapy of mRCC patients at second line.

Outcome of active surveillance prior to systemic target therapy in patients with metastatic renal cell carcinoma.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 444-444
Author(s):  
Nobuaki Matsubara ◽  
Hirofumi Mukai ◽  
Yoichi Naito ◽  
Kuniaki Itoh
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Active Surveillance ◽  
Treatment Option ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progressive Disease ◽  
Target Therapy

444 Background: The clinical course of metastatic renal cell carcinoma (mRCC) has a wide spectrum that ranges from indolent to rapidly progressive disease. Initial active surveillance (AS) followed by deferred systemic target therapy might be a treatment option in a subpopulation of patients with indolent mRCC. However, very few studies have been published about AS and its outcome as well as potential predictive factor that might be associated with indolent mRCC. Here, we report clinical outcomes of mRCC patients who initially were monitored by AS. Methods: We retrospectively reviewed and analyzed the clinical and pathological data of mRCC patients who initially were monitored by planned AS prior to systemic therapy due to asymptomatic or slowly progressive disease at National Cancer Center Hospital East between 2000 and 2011. The primary outcome measures were progression-free survival (PFS) and overall survival (OS). Results: A total of 29 patients were eligible for this analysis. The median age at diagnosis was 69 years, and all patients had a good general condition with a performance status of 0 or 1. A total of 65% of patients had recurrent disease and 35% were in stage 4. All of the patients had undergone nephrectomy, and 86% had clear cell carcinoma. None of the patients was categorized into a poor risk group according to both MSKCC and Heng criteria. The median follow-up period was 35.4 months. During the follow-up period, disease progression was observed in 72% of patients but only 14% died. The median PFS time was 26.1 months. After disease progression was observed, only 58% of these patients received treatment or intervention. The median OS have not been reached yet, but 12, 24 and 48 months OS rates were 96.4, 88.7 and 83.8%, respectively. Conclusions: PFS and OS of patients who underwent AS were extremely favorable. For these indolent subpopulations, AS might be a treatment option, so toxic and expensive systemic target therapy could be deferred for a significant period of time without prognostic disadvantage. However, further observational study with a larger sample size might be needed in order to identify the exact subpopulation eligible for AS.

721 TSH VALUES AS A PROGNOSTIC BIOMARKER OF SUNITINIB EFFICACY IN METASTATIC RENAL CELL CARCINOMA PATIENTS

2011 ◽  
Vol 10 (2) ◽  
pp. 230
Author(s):  
A. Lapini ◽  
V. Baldazzi ◽  
R. Tassi ◽  
F. Lanzi ◽  
M. Carini ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Biomarker

scholarly journals Targeted Therapy for Metastatic Renal Carcinoma: An Update

2014 ◽  
Vol 1 (6) ◽  
pp. 63-73 ◽  
Author(s):  
Rodrigo Donalisio da Silva ◽  
Diedra Gustafson ◽  
Leticia Nogueira ◽  
Priya N. Werahera ◽  
Wilson R Molina ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Target Therapy ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
New Drugs ◽  
Metastatic Rcc

Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the treatment of advanced renal cell carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of relevant studies published in PubMed between 2000 and 2014 were analyzed by two authors. Abstracts were selected if they were published in English, data reported was of phase II or III clinical trials, and outcomes followed FDA approval.  If consensus between the two authors was achieved, they were included in the review. Key words used were “target therapy” and “metastatic renal cell carcinoma”. The results of the studies analyzed in this review support the benefits of targeted therapy in metastatic RCC. These include improved progression-free survival, overall survival, and quality of life as well as reduced toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC makes these drugs a preferred option as a primary treatment for these patients. 

Sign in / Sign up

Export Citation Format

Share Document